These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36843563)

  • 1. Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence.
    Tavajohi R; Shahrami B; Rostami T; Kiumarsi A; Honarmand H; Hadjibabaie M
    J Oncol Pharm Pract; 2023 Jun; 29(4):927-933. PubMed ID: 36843563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
    Floeter AE; McCune JS
    J Oncol Pharm Pract; 2017 Jul; 23(5):344-349. PubMed ID: 27208016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution.
    Hughes K; Garrity L; Nelson AS; Lane A; Teusink-Cross A
    Pediatr Transplant; 2021 Jun; 25(4):e14026. PubMed ID: 33894096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
    Soni S; Skeens M; Termuhlen AM; Bajwa RP; Gross TG; Pai V
    Pediatr Blood Cancer; 2012 Oct; 59(4):762-4. PubMed ID: 22378696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant.
    Chaguaceda C; Aguilera-Jiménez V; Gutierrez G; Roura J; Riu G
    Int J Clin Pharm; 2020 Apr; 42(2):351-354. PubMed ID: 32026356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation.
    Tsujimoto SI; Shirai R; Utano T; Osumi T; Matsumoto K; Shioda Y; Kiyotani C; Uchiyama T; Deguchi T; Terashima K; Tomizawa D; Matsumoto K; Kato M
    Int J Hematol; 2020 Mar; 111(3):463-466. PubMed ID: 31863341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients.
    Akiyama K; Kume T; Fukaya M; Shiki I; Enami T; Tatara R; Shino M; Ikeda T
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):717-721. PubMed ID: 30083882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation.
    Nakashima T; Tanaka T; Koido K; Nishibuchi Y; Hashimoto H; Ito A; Inamoto Y; Kurosawa S; Kim SW; Fukuda T; Terakado H
    Int J Hematol; 2019 Jun; 109(6):694-699. PubMed ID: 30915718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.
    Ward J; Kletzel M; Duerst R; Fuleihan R; Chaudhury S; Schneiderman J; Tse WT
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1612-21. PubMed ID: 26025482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M; Jacobsohn D; Duerst R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
    Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
    Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
    Fernandez HF; Tran HT; Albrecht F; Lennon S; Caldera H; Goodman MS
    Biol Blood Marrow Transplant; 2002; 8(9):486-92. PubMed ID: 12374453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan.
    Diaz-Carrasco MS; Olmos R; Blanquer M; Velasco J; Sánchez-Salinas A; Moraleda JM
    Int J Clin Pharm; 2013 Jun; 35(3):339-43. PubMed ID: 23575621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
    Hamidieh AA; Hamedani R; Hadjibabaie M; Amini M; Sadrai S; Ghavamzadeh A
    Pediatr Hematol Oncol; 2010 Oct; 27(7):529-33. PubMed ID: 20677921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
    Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
    Berger K; Schopohl D; Rieger C; Ostermann H
    Support Care Cancer; 2015 Dec; 23(12):3447-54. PubMed ID: 25773673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased Systemic Busulfan Exposure After Oral Dosing With Concomitant Levetiracetam Compared With Phenytoin.
    Artul T; Henig I; Nassar L; Yehudai-Ofir D; Scherb I; Lurie Y; Efrati E; Zuckerman T; Kurnik D
    Ther Drug Monit; 2022 Jun; 44(3):414-418. PubMed ID: 34739424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
    Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.